Stryker said that its OptaBlate bone tumor ablation system (OptaBlate) received 510(k) clearance from the U.S. Food and Drug Administration. The addition of the OptaBlate technology to Stryker's Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures.
"Stryker's new bone tumor ablation (BTA) system is a significant improvement on existing technology and builds on Stryker's IVS portfolio," said Dr. Anthony Brown, a Vascular and Interventional Radiologist at Radiology Imaging Associates, CO. "There is no more deserving patient population for our attention and intervention; OptaBlate will change lives."
As Stryker's first Interventional Oncology technology, OptaBlate optimizes all aspects of the procedure—from set-up to ablation. Featuring four probes and Stryker's unique and patented microinfusion technology, OptaBlate allows physicians to easily customize their procedure and reduce ablation time by three minutes.1
Specific key features of the system include:
- Treatment of two vertebral body levels at once using a bipedicular approach
- Quicker, more consistent ablation
- Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring
